Since joining the NIDA Clinical Trials Network in 2002, the Southwest Node has made a substantial and singular contribution to the research activities of the CTN. The Southwest Node has successfully completed six multi-site trials, as well two studies focusing on Native Americans, two survey studies, and several ancillary and platform Studies. We are currently serving as Lead Node for CTN 0047, Screening, Motivational Assessment, and Referral for Treatment in Emergency Departments (SMART-ED). Beyond participation in protocols, the Node has been highly productive in the areas of protocol development, training, committee work, and dissemination. The Node has made an outstanding contribution to advancing the clinical science of addictions treatment in minority and other underserved populations. Of the multi-site trial participants recruited at the Southwest Node, 71% were Hispanic and 7% were Native American, not counting 427 participants thus far in the two Native American protocols. The Node has managed grant funds prudently and efficiently, requesting and spending only what is necessary to achieve our scientific objectives. For the renewal period, the Southwest Node will consist of its RRTC, the University of New Mexico Center on Alcoholism, Substance Abuse, and Addictions (CASAA), and affiliated investigators at the University of New Mexico;5 primary CTPs, all of which have already collaborated extensively with Node investigators;and 6 secondary CTPs representing a wide range of medical, dental, and psychiatric treatment settings. Strengths of the Southwest Node include: 1) a well-established track record of clinical trials with both behavioral treatments and pharmacotherapies;2) longstanding experience in the development and evaluation of innovative treatments for addictions;3) extensive experience with minority and other underserved populations, and demonstrated ability to recruit them;4) expertise in research on dissemination and training;and 5) geographic representation of the American Southwest. Our agenda for the renewal period will build on our strengths, with four proposed foci of research leadership: 1) implementing addiction treatment in medical settings;2) optimizing addiction treatment for minority populations;3) using the family to enhance treatment outcome;and 4) pharmacologic treatment of opioid dependence.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10DA015833-10S2
Application #
8453815
Study Section
Special Emphasis Panel (ZDA1-KXH-C (04))
Program Officer
Dobbins, Ronald
Project Start
2002-09-30
Project End
2015-08-31
Budget Start
2011-09-01
Budget End
2012-08-31
Support Year
10
Fiscal Year
2012
Total Cost
$244,000
Indirect Cost
$82,410
Name
University of New Mexico
Department
Psychology
Type
Schools of Arts and Sciences
DUNS #
868853094
City
Albuquerque
State
NM
Country
United States
Zip Code
87131
Levran, Orna; Correa da Rosa, Joel; Randesi, Matthew et al. (2018) A non-coding CRHR2 SNP rs255105, a cis-eQTL for a downstream lincRNA AC005154.6, is associated with heroin addiction. PLoS One 13:e0199951
Pan, Yue; Liu, Hongmei; Metsch, Lisa R et al. (2017) Factors Associated with HIV Testing Among Participants from Substance Use Disorder Treatment Programs in the US: A Machine Learning Approach. AIDS Behav 21:534-546
Osterman, Robin; Lewis, Daniel; Winhusen, Theresa (2017) Efficacy of motivational enhancement therapy to decrease alcohol and illicit-drug use in pregnant substance users reporting baseline alcohol use. J Subst Abuse Treat 77:150-155
Winhusen, Theresa; Lewis, Daniel (2017) Cigarette smoking in pregnant substance users: Association with substance use and desire to quit. J Addict Dis 36:88-91
Horn, Brady P; Crandall, Cameron; Forcehimes, Alyssa et al. (2017) Benefit-cost analysis of SBIRT interventions for substance using patients in emergency departments. J Subst Abuse Treat 79:6-11
Sharma, Gaurav; Oden, Neal; VanVeldhuisen, Paul C et al. (2016) Hair analysis and its concordance with self-report for drug users presenting in emergency department. Drug Alcohol Depend 167:149-55
Hernández, Diana; Feaster, Daniel J; Gooden, Lauren et al. (2016) Self-Reported HIV and HCV Screening Rates and Serostatus Among Substance Abuse Treatment Patients. AIDS Behav 20:204-14
Houck, Jon M; Forcehimes, Alyssa A; Davis, Meredith M A et al. (2016) Qualitative and quantitative feedback following workshop training in evidence-based practices: A dissemination study. Prof Psychol Res Pr 47:413-417
Gooden, Lauren; Metsch, Lisa R; Pereyra, Margaret R et al. (2016) Examining the Efficacy of HIV Risk-Reduction Counseling on the Sexual Risk Behaviors of a National Sample of Drug Abuse Treatment Clients: Analysis of Subgroups. AIDS Behav 20:1893-906
Schackman, Bruce R; Leff, Jared A; Barter, Devra M et al. (2015) Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. Addiction 110:129-43

Showing the most recent 10 out of 57 publications